Checking In and Updates

I hope you and your family are well amidst these uncertain, difficult times for our nation. We continue to face the COVID-19 crisis, but horrific deaths and riots have also shaken many over the last few weeks. I mourn with all of those who are hurting over the unjust deaths of George Floyd, Breonna Taylor, and Ahmaud Arbery, as well as with those who have had their lives or livelihoods endangered amidst the violent riots. I pray that justice will be swiftly served and also that law and order will be restored. Both are vital for working towards trust, respect, and unity among all people going forward. Know that your safety and well-being are top priorities for me right now and I am doing all I can to those ends. If my staff can be of any help right now, please don't hesitate to reach out. In the meantime, here are a few updates that I hope are useful to you.

COVID-19 Quick Updates

• The Energy & Commerce Committee has released a report on testing progress in the U.S. and on how testing needs to be utilized to avoid a second wave of infection in the fall.
• In recently updated guidance, the CDC has clarified that the virus does not easily spread by touching surfaces or objects.
• The U.S. has now performed approximately over 21 million tests. America continues to lead the world in testing efforts.
• The Trump Administration has announced the "Operation Warp Speed" effort, a national program for expediting the development and distribution of a COVID-19 vaccine. President Trump has appointed Moncef Slaoui as chief advisor to the program. Slaoui formerly served as Chairman of Global Research and Development and Chairman of Global Vaccines at GlaxoSmithKline, where he headed the creation of five major novel vaccines. Operation Warp Speed has selected 5 potential vaccine candidates to prioritize for accelerated development.
• The FDA is overseeing clinical trials for 130 potential COVID-19 drugs.
• FEMA, the CDC, and HHS recently released a tool guide on local reopening guidance.

To read full newsletter, click here.